Therapeutic compositions with enhanced bioavailability |
| OF THE INVENTION This invention relates to compositions of a drug with a water soluble polymer ... |
|
Medicament adsorbates and their preparation |
| In particular, it has been found that a good tasting medicament adsorbate is produced from ... |
|
Sustained release formulations |
| We claim: 1. In combination, a drug suitable for oral delivery and a delivery system for sustained ... |
|
Water dispersible gemfibrozil compositions |
| What is claimed is: 1. A water-dispersible formulation of gemfibrozil comprising finely divided ... |
|
Method and composition for enhancing the effect of indirect-acting sympathomimetic amines |
| OF SPECIFIC EMBODIMENTS In accordance with this invention, tyrosine or a tyrosine precursor such ... |
|
1-azabicycloalkane derivatives, their preparation process and their use as medicaments |
| What is claimed is: 1. A compound of formula (I) ##STR5## in which n represents the number 1, R.sub.... |
|
Iron citrate complex, process for its production, and its pharmaceutical |
| We claim: 1. An iron citrate micellar complex, which is a brown solid having the properties set out ... |
|
Specifically .beta.-.beta. cross-linked hemoglobins and method of preparation |
| The present invention provides a modified hemoglobin comprising hemoglobin which is cross-linked ... |
|
|
Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
| Details |
Inventors: Vincent, Michel; Remond, Georges; Laubie, Michel;
Assignee: Adir (Neuilly-sur-Seine, FR)
Primary Examiner: Daus; Donald G.
Assistant Examiner: Hendricks; G.
Attorney, Agent or Firm: Hueschen; Gordon W.
Compounds of the general formula: ##STR1## wherein: the ring A is saturated and n=0 or 1, or the ring A is a benzene ring and n=1, R.sub.1 represents a lower alkyl group which can carry an amino group, R.sub.2 represents a hydrogen atom or a lower alkyl group, R.sub.3 represents a straight or branched alkyl group, a mono- or di-cycloalkylalkyl or phenylalkyl group having no more than a total of 9 carbon atoms, or a substituted alkyl group, and also the salts thereof. These compounds are useful as therapeutic drugs. |
|
DETAILED DESCRIPTION We claim: 1. A compound selected from the group consisting of iminodiacid compounds having the formula: ##STR20## wherein R. sub. 1 represents lower-alkyl having 1 to 4 carbon atoms, inclusive, R. sub. 2 represents hydrogen or lower-alkyl having 1 to 4 carbon atoms, inclusive, R. sub. 3 is --CH. sub. 2 CH. sub. 2 --CH. sub. 3, in racemic form or as an optical isomer, a salt thereof with a pharmaceutically-acceptable inorganic or organic base, and an addition salt thereof with a pharmaceutically-acceptable inorganic or organic acid. 2. A compound of claim 1, in which R. sub. 1 is a methyl radical. 3. (2S)-1-{N[(1RS)-1-ethoxycarbonylbutyl]-(S)-alanyl}-2-carboxy perhydroindole, its (S)-isomer or the sodium salt of these. 4. A pharmaceutical composition containing as active ingredient at least one compound according to claim 1, in conjunction with an inert, non-toxic pharmaceutically-acceptable carrier or excipient. 5. A pharmaceutical composition containing as active ingredient a compound according to claim 3, in conjunction with an inert, non-toxic pharmaceutically-acceptable carrier or excipient. 6. A method for treating a patient suffering from hypertension, which comprises administering to said patient a therapeutically effective dose of a compound according to claim 1. 7. A method for treating a patient suffering from hypertension, which comprises administering to said patient a therapeutically-effective dose of a compound according to claim 3.
Description:
The present invention relates to new substituted imino-diacids, and more particularly to substituted azabicycloalkanedicarboxylic acids, their preparation and pharmaceutical compositions which contain them. The invention relates specifically to the compounds having the general formula ##STR2## wherein: the ring A is saturated and n=0 or 1, or the ring A is a benzene ring and n=1, R. sub. 1 represents a lower alkyl group having from 1 to 4 carbon atoms which can carry an amino group, R. sub. 2 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, R
|
| Related patents |
|
|
2-Azasfiro[4.(3+N)]-3-carboxylic acid derivatives, a process for their preparation, agents containing these derivatives and their use
We claim: 1. A compound of the formula I ##STR11## in which n denotes 1, 2, 3 or 4, R denotes (C.sub.1 -C.sub.6)-alkyl, (C.sub.2 -C.sub.6)-alkenyl, (C.sub.5 -C.sub.9)-...
|
|
|
N-Acyl hexahydroindole-2-carboxylic acids and anti-hypertensive use thereof
We claim: 1. A compound of the formula I, ##STR24## in which n denotes 0 to 1, R denotes hydrogen, (C.sub.1 to C.sub.6)-alkyl or aralkyl having 7 to 9 C atoms, R.sup.1 ...
|
|
|
Bicyclic amino acids as intermediates in the preparation of tricyclic amino acids and processes for their preparation
We claim: 1. A compound of the formula III ##STR19## in which A denotes --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --, the H atoms on C-2 and C-6 are in the cis-...
|
|
|
Substituted N-carboxymethyl-aminoacylaminoalkanoic acids useful as antihypertensive agents
OF THE INVENTION AND PREFERRED EMBODIMENTS In its broadest aspect, the present invention relates to novel substituted N-carboxymethyl-aminoacylaminoalkanoic acid ...
|
|
|
Racemates of optically active bicyclic imino-alpha-carboxylic esters
We claim: 1. A diasteromic salt of i. a bicyclic imino-.alpha.-carboxylic ester of the formulae Ia or Ib ##STR15## in which the two bridgehead hydrogen atoms have the ...
|
|
|
Disubstituted proline derivatives
We claim: 1. A compound of the formula I ##STR15## in which R.sup.1 and R.sup.2 together represent one of the chains --(CH.sub.2).sub.n -- or --(CH.sub.2).sub.p --CH.dbd....
|
|
|
Derivatives of cis, endo-2-azabicyclo[5.3.0]decane-3-carboxylic acid, and their use for treating hypertension
We claim: 1. A compound of the formula I ##STR11## in which the hydrogen atoms on the bridgehead C atoms 1 and 5 have the cis-configuration relative to one another and ...
|
|
|
Carboxyalkyl dipeptides and anti-hypertensive use thereof
We claim: 1. A compound represented by the formula ##STR12## and the pharmaceutically acceptable salts thereof, wherein R and R.sup.6 are the same or different and are ...
|
|
|
Optically active bicyclic imino-alpha-carboxylic esters
We claim: 1. A compound of the formulae Ia or Ib essentially free of its racemate, and salts of said compound, ##STR15## in which the two bridgehead hydrogen atoms have ...
|
|
|
5-HT.sub.3 receptor antagonists for treatment of cough and bronchoconstriction
I claim: 1. A method of treatment of cough and/or bronchoconstriction in mammals, which method comprises the administration to the mammal in need of such treatment, an ...
|
|
|